AMRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Amneal Pharmaceuticals Inc (AMRX) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the stock shows some positive indicators such as bullish moving averages and favorable analyst ratings, the lack of significant recent news, weak financial performance in the latest quarter, and neutral trading sentiment suggest that this is not an optimal entry point for investment. The investor may consider monitoring the stock for further developments or better entry opportunities.
The technical indicators show a bullish trend with moving averages (SMA_5 > SMA_20 > SMA_200). MACD is positive at 0.147, indicating upward momentum, but RSI at 67.947 is in the neutral zone, suggesting no clear overbought or oversold conditions. Key resistance levels are at 13.115 and 13.401, with support at 12.191 and 11.905.
Analysts from Goldman Sachs, Truist, and JPMorgan have raised price targets to $17-$18, maintaining Buy or Overweight ratings.
Bullish moving averages and positive MACD indicate a favorable technical trend.
Revenue increased by 11.47% YoY in Q4 2025.
Net income dropped significantly by -212.85% YoY in Q4 2025, and EPS fell by -210.00% YoY.
No recent news or event-driven catalysts to support immediate growth.
Neutral sentiment from hedge funds and insiders, with no significant trading trends.
In Q4 2025, revenue increased by 11.47% YoY to $814.3M, but net income dropped by -212.85% YoY to $35.1M. EPS fell by -210.00% YoY to 0.11. Gross margin improved slightly by 1.45% YoY to 36.5%. Overall, the financial performance is mixed, with growth in revenue but significant declines in profitability.
Analysts have consistently raised price targets to $17-$18 and maintained Buy or Overweight ratings. The long-term growth thesis is supported by strong EBITDA guidance for FY26 despite softer GRx performance and slightly below-Street revenue guidance.
